May 20, 2019
KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences
– Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented…
Pharmaceuticals, Biotechnology and Life Sciences
– Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented…